Nav: Home

Immunotherapy against bee stings in some cases incomplete

May 16, 2017

Summer is approaching, and for many allergy sufferers this means it is time to start fearing bee stings. "Allergic reactions to insect venoms are potentially life-threatening, and constitute one of the most severe hypersensitivity reactions," explains PD Dr. Simon Blank, research group leader at the Center of Allergy & Environment (ZAUM), a joint undertaking by the Helmholtz Zentrum München and the TUM.

This is where allergen-specific immunotherapy, commonly known as allergy shots, can help. The treatment involves injecting very small doses of the venom under the patient's skin. The idea is to force the body to become accustomed to the poison and consequently to put an end to the immune system's excessive reaction. According to Blank and his team, however, it may be necessary to improve the procedure.

Allergens strongly underrepresented

"We now know that bee venom is a cocktail of many different substances. In particular, there are five components that are especially relevant for allergy sufferers," Blank explains. "In our current investigation of commercial preparations, however, we were able to show that these so-called major allergens are not present everywhere at sufficient levels, and some allergens are seriously underrepresented!"

While some preparations contained uniform levels of all venom components, in others up to three of the five allergens were present at levels that were too low, according to the authors. The scientists cannot concretely state exactly what this means for the therapeutic success. "So far, studies have not been able to prove how significant this is for the treatment. Because more than six percent of the patients are sensitized only against these three allergens, however, their underrepresentation could affect the treatment success, at least for these patients."

Customized immunotherapy against bee stings?

Consequently, if patients react to specific allergens in bee venom but these are possibly not found in the preparations at sufficient levels, the question that must be asked is what good does immunotherapy against bee stings do for the individual.

ZAUM Director Prof. Dr. Carsten Schmidt-Weber sees it like this: "The vast majority of patients benefit from such a treatment. A desirable objective that results from this work, however, would be for patients to receive a customized treatment in the future. This would be a preparation with exactly the allergens to which the particular patient actually reacts." Due to costs and the relatively small number of patients, however, such developments are still a long way off.
-end-
Further Information

Background:

For their analysis, the researchers first produced antibodies against the five individual bee venom allergens in order to be able to detect these substances. Specifically, this involved proteins Api m 1, 2, 3, 5 and 10. The abbreviation Api m comes from the Latin term for the honey bee, Apis mellifera. Its venom is correspondingly called apitoxin. The researchers then tested the content of these components in four different preparations for allergen immunotherapy, while also examining different batches. Some preparations contained sufficient levels of all allergens, but some did not.

Specific studies are needed to provide findings regarding the effects on the treatment. Recently, however, a different study (Frick et al., JACI 2016) was able to show that sensitization principally with respect to Api m 10 constitutes an increased risk for the failure of the immunotherapy. The study did not examine if this is associated with a low content of Api m 10 in the preparations.

Original Publication:

Blank, S. et al. (2017): Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy. Human Vaccines and Immunotherapeutics, DOI: 10.1080/21645515.2017.1323603

The Helmholtz Zentrum München, the German Research Center for Environmental Health, pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München is headquartered in Neuherberg in the north of Munich and has about 2,300 staff members. It is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members.

The Center of Allergy & Environment (ZAUM) in Munich is a joint undertaking by the Helmholtz Zentrum München and the Technical University of Munich (TUM). This cooperation, which is the only one of its kind in the German research landscape, is dedicated to interdisciplinary basic research and forms a link between clinicians at the hospital and clinical research staff at the university. Thanks to this approach, findings about the mechanisms that lie behind allergies are translated into preventive and therapeutic measures. The development of effective, individually tailored treatments enables better care to be provided for allergy-sufferers.

Technical University of Munich (TUM) is one of Europe's leading research universities, with more than 500 professors, around 10,000 academic and non-academic staff, and 40,000 students. Its focus areas are the engineering sciences, natural sciences, life sciences and medicine, com-bined with economic and social sciences. TUM acts as an entrepreneurial university that promotes talents and creates value for society. In that it profits from having strong partners in science and industry. It is represented worldwide with a campus in Singapore as well as offices in Beijing, Brussels, Cairo, Mumbai, San Francisco, and São Paulo. Nobel Prize winners and inventors such as Rudolf Diesel, Carl von Linde, and Rudolf Mößbauer have done research at TUM. In 2006 and 2012 it won recognition as a German "Excellence University." In international rankings, TUM regularly places among the best universities in Germany.

The Institute of Allergy Research (IAF) investigates the molecular mechanisms behind the development of allergies, which are on the rise around the world. Through intensive cooperation among scientists and clinicians on individual approaches to prevention, the IAF is working to halt this epidemiological spread. In the therapeutic area, the institute's scientists want to develop new approaches specifically targeted at the patients. The IAF works with the Technische Universität München in the joint Center of Allergy & Environment (ZAUM) facility. The IAF is also a member of the Cluster Allergy and Immunity (CAI) and the German Center for Lung Research (DZL).

Contact for the media:

Department of Communication, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 2238 - Fax: +49 89 3187 3324 - E-mail: presse@helmholtz-muenchen.de

Scientific Contact at Helmholtz Zentrum München:

PD Dr. Simon Blank, Helmholtz Zentrum München - German Research Center for Environmental Health, Institute of Allergy Research & Center of Allergy and Environment, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 4140 2625 - E-mail: simon.blank@helmholtz-muenchen.de

Helmholtz Zentrum München - German Research Center for Environmental Health

Related Immunotherapy Articles:

Immunotherapy prior to surgery is effective in colon cancer
Patients with colon cancer, but no distant metastases, can benefit from a short course of immunotherapy while waiting for their surgery, as it can cause tumours to shrink substantially or clear up in a very short time.
Researchers discover potential boost to immunotherapy
Mount Sinai researchers have discovered a pathway that regulates special immune system cells in lung cancer tumors, suppressing them and allowing tumors to grow.
Predicting immunotherapy success
Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments.
Designer probiotic treatment for cancer immunotherapy
Columbia Engineers have engineered probiotics to safely deliver immunotherapies within tumors, including nanobodies against two proven therapeutic targets -- PD-L1 and CTLA-4.
Cancer vaccine could boost the effectiveness of immunotherapy
Supercharging the mutation rate in cancer cells can create a powerful vaccine that is able to boost the effectiveness of immunotherapy, a major new study reports.
Math models add up to improved cancer immunotherapy
A merger of math and medicine may help to improve the efficacy of immunotherapies, potentially life-saving treatments that enhance the ability of the patient's own immune system to attack cancerous tumors.
B cells linked to effective cancer immunotherapy
Cancer patients responded better to immunotherapy and had a better prognosis if their melanoma tumors contained specific clusters of B cells, according to new research from Lund University in Sweden.
B cells: New allies in sarcoma immunotherapy?
How can we improve and better personalize the treatment of soft tissue sarcomas, these particularly resistant and aggressive forms of cancer?
Transition to exhaustion: clues for cancer immunotherapy
Emory research on immune cells 'exhausted' by chronic viral infection provides clues on how to refine cancer immunotherapy.
Using artificial intelligence to determine whether immunotherapy is working
Currently, only about 20% of all cancer patients will actually benefit from costly immunotherapy.
More Immunotherapy News and Immunotherapy Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.